AR and breast cancer: So as to confirm the role of CKIs in AR+/TNBC breast cancer, stage I-II trials NCT02605486 and BRE15-024 (NCT03090165) are surveying whether Palbociclib in combination with Bicalutamide improve the PFS, CBR of metastatic patients and whether Ribociclib with Bicalutamide promote CBR of TNBC, separately.